Nature Aging: Harvard Scientists Uncover Key Role of Peroxisomes in Extending Life Through Fasting
A study published in Nature Aging revealed that aging disrupts peroxisome function (cellular organelles), triggering a cascade of metabolic disorders. Dietary restriction (fasting) extends life precisely by maintaining peroxisome function, opening a new target for rejuvenating interventions.
The Peroxisome Paradox: Why Fasting Works and What to Do When It Stops
[The Core]: What's Really Happening
On May 20, 2026, a study published in Nature Aging turned our understanding of dietary restriction on its head.
Professor William Mair's team at Harvard University showed that fasting extends life not through signal amplitude (as many thought), but by maintaining a specific structure—peroxisomes.
Peroxisomes are tiny vesicles in cells that handle fatty acid oxidation and hydrogen peroxide detoxification. Before this study, they were considered "support staff"—useful but not critical. The main roles in aging were assigned to mitochondria (power plants) and lysosomes (garbage disposals).
The Harvard researchers conducted experiments on C. elegans nematodes and mice. They found that in young organisms, fasting sharply increases the expression of genes responsible for peroxisome function. In old ones, it does not.
Then came the most interesting part. It turned out that peroxisomes don't age gradually but by a "switch-off" principle. The key protein is peroxin PRX-5, responsible for transporting other proteins into the peroxisome. With age, PRX-5 levels drop. Without it, the peroxisome loses its ability to utilize long-chain fatty acids. Fats begin to accumulate as giant, pathological lipid droplets that the cell cannot break down even during fasting.
This triggers a cascade: fat accumulation → mitochondrial damage (they start producing reactive oxygen species, overheat, and stop making ATP) → cell death.
And the knockout experiment: if PRX-5 expression is artificially suppressed in a young individual, fasting stops extending life. Conversely, if an old individual's cells are forced to produce more PRX-5 (even without fasting), the animal lives longer and remains metabolically flexible.
"We found that loss of metabolic flexibility starts with peroxisomes, not mitochondria. This changes the hierarchy of aging," Mair wrote in his LinkedIn post commenting on the publication.
Timeline and Context
2016–2019: Early studies on peroxisomes' role in aging are scattered. It's shown that in some neurodegenerative diseases (adrenoleukodystrophy), peroxisome defects lead to early death, but no one linked this to normal aging.
2021: Mair's group publishes work showing that metabolic flexibility declines with age due to lipid droplet accumulation. But the mechanism remains unclear.
2023: Preliminary data appear at conferences. Researchers notice that in old animals, PRX-5 levels don't rise after fasting, unlike in young ones.
May 20, 2026: Publication in Nature Aging. Authors are Arpit Sharma (now PI at Tufts University) and his colleagues from Harvard.
Key figures:
- In young worms, fasting increased peroxisome activity by 3–5 times.
- In old worms, by no more than 30%.
- Deleting the PRX-5 gene led to a complete loss of fasting's effect on lifespan (signal disappeared into statistical noise).
- Overexpression of PRX-5 increased the lifespan of old worms by about 20–25% even on a normal diet.
Who Wins and Who Loses
Winners (obvious):
- Harvard T.H. Chan School of Public Health. They've just made a name for themselves in gerontology for the next 5–10 years. Professor Mair is now in every other headline about aging. The lab will receive grants to study PRX-5 as a drug target. Funding amount? A typical NIH R01 on such a topic is $1.5–2.5 million over 5 years.
- Companies developing fasting mimetics. Resveratrol, metformin, spermidine, nicotinamide riboside—all have tried to mimic fasting effects but without the mechanism shown in Nature Aging. Now they have a clear target: PRX-5 and the NHR-49/PPAR-alpha pathway. If any mimetic boosts PRX-5 activity or supports peroxisome gene expression, it gains scientific backing.
- Proponents of intermittent fasting. Now they have a molecular explanation for why it works: not just "you eat fewer calories," but "you activate a specific protein in specific organelles."
Losers:
- The mitochondrial theory of aging in its pure form. For decades, it was thought that everything starts with mitochondria: they get damaged by reactive oxygen species, energy drops, cells age. The Harvard work flips the sequence: peroxisomes fail first (PRX-5 malfunction), lipid droplets accumulate, and only then do mitochondria suffer. This doesn't refute the mitochondrial theory but lowers its priority.
- Producers of ready-made diet plans based solely on calorie counting. Their argument "eat less, live longer" now sounds like an oversimplification. It's much more important that the diet is composed to support peroxisome function (less long-chain saturated fats, more omega-3 sources, and the possibility of periodic fasting).
What the Media Isn't Saying
*Non-obvious Insight #1: This mechanism doesn't work in people with certain genetic variants*
Here's what press releases are silent about.
Humans have several isoforms of the PEX5 protein (analogous to worm PRX-5). Some single nucleotide polymorphisms in the PEX5 gene are associated with reduced stability. Such people have inherently lower peroxisome activity. This means fasting will have a much weaker effect on them—or none at all.
Similarly, mutations in the PEX13 gene (another component of the peroxisome importer) occur with a frequency of about 1 in 50,000 and lead to Zellweger syndrome—a fatal condition. But subclinical variants with partial loss of function may be much more common (possibly 1–3% of the population).
For these people, the advice "eat less" won't work. They will need direct therapy—PEX5 modulators or activators of alternative fat oxidation pathways (e.g., through PPAR-alpha).
Non-obvious Insight #2: The study doesn't explain why peroxisomes break down first
They have a correlation: PRX-5 levels drop with age. But why does it drop? That's not yet known.
Possible reasons (which Mair and his team are likely investigating now): accumulation of damaged proteins that can't fold properly and clog the import machinery; oxidative stress that modifies PRX-5 and disables it; epigenetic silencing of the prx-5 gene with age.
If it turns out that PRX-5 is turned off due to DNA methylation, this could be reversed with DNA methyltransferase inhibitors (e.g., azacitidine). Azacitidine is already on the market (for myelodysplasia, costing about $1,200 per injection). This would mean that repurposing an existing drug could restore the fasting response in old people.
But no press release mentions this—too speculative.
Non-obvious Insight #3: The C. elegans model (nematode) is not ideal for human fat metabolism
The worm has no liver or adipose tissue as we understand them. Its lipid droplets are in intestinal cells and hypodermis. Worm fat metabolism differs greatly from human (we have lipoproteins circulating in blood, hormonal regulation by leptin and insulin, different types of fat depots).
Yes, the authors confirmed key findings in mice (showing that fasting in old mice doesn't boost peroxisome activity in the liver as it does in young ones). But mice aren't humans. Human livers contain thousands of peroxisomes, but their role in fat metabolism is still underestimated. Clinical studies on modulating PEX5 in humans aren't even planned yet.
Media write as if "the anti-aging drug is just around the corner." In reality, from a Nature Aging publication to the first phase of clinical trials with a human analog of PRX-5 will take 7–10 years (if at all).
Forecast: Next 30 Days and 90 Days
30 days (by end of June 2026):
- Wave of follow-up studies. Labs worldwide will start checking whether known geroprotectors (rapamycin, metformin, acarbose) affect PRX-5 levels and peroxisome activity in mouse liver. Those showing positive results will get a strong argument for their molecules. Expect preprints on bioRxiv within a month.
- Interest from supplement companies. PRX-5 is a protein; you can't take it orally. But inducers of PEX5 transcription (small molecules that boost gene expression) could be found. Companies like metabolic startups (e.g., MetroBiotech or Fauna Bio) will start screening programs. The cost of such screening is about $2–5 million over 6 months.
- Popular press coverage. The New York Times, The Guardian, BBC will write about "the secret of fasting." This will attract a broad audience and may spark another wave of interest in intermittent fasting (as seen after Nobel laureate Yoshinori Ohsumi's work on autophagy in 2016).
90 days (by end of August 2026):
- Patent filings. Harvard University and the Howard Hughes Medical Institute (HHMI), where Mair works, will file patent applications for methods of modulating peroxisome activity to extend lifespan. This is standard. A USPTO patent application costs $10,000 to $30,000 to prepare and file. It will be publicly disclosed only after 18 months.
- Clinical trials will not start—100% certain. Too early. But an observational study might appear: in elderly people with different dietary patterns, peroxisome activity in liver biopsies will be measured (biopsy is invasive, so unlikely to be done en masse). More realistic: a mouse study with liver-specific PEX5 knockout to show whether liver peroxisomes alone are sufficient for the effect or other tissues matter.
- Talk of "PRX-5 as a biomarker of aging." Several companies (e.g., Elysium Health or InsideTracker) may offer to measure PRX-5 protein levels in blood samples as a marker of metabolic age. The cost of such a test: $200 to $500. Will it have clinical value? Unclear, but marketing potential is huge.
Main forecast:
In 2–3 years, we'll see attempts to create a drug that boosts peroxisome activity without the need to fast. The most likely candidate is a PPAR-alpha agonist from the fibrate class (e.g., fenofibrate or pemafibrate), which increases expression of β-oxidation genes in peroxisomes. Fibrates are already approved for hypertriglyceridemia and cost about $30–100 per month of therapy in the US.
The paradox is that we've been using fibrates for decades without knowing their true geroprotective mechanism. Now, perhaps, they'll have a second life as agents that extend metabolic youth.
But let's add a fly in the ointment: fasting is a systemic signal affecting hundreds of genes. A PPAR-alpha agonist activates only one pathway. The effect will likely be weaker than fasting itself. Mair's study shows why fasting works but doesn't provide a simple shortcut.
— Editorial Team
